VivoSeq
Other

Medium Chain Acyl-Coa Dehydrogenase Deficiency

2

Pipeline Programs↗

1

Active Trials↗

2

Companies Involved↗

Medium Chain Acyl-Coa Dehydrogenase Deficiency is an early-stage landscape with 2 programs across 2 companies. The most active players are Ultragenyx, Liminal BioSciences Ltd..

Intelligence

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Ultragenyx logo

Ultragenyx

1 program

Phase 2L

Liminal BioSciences Ltd.

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 22

Triheptanoin

Ultragenyx

Sodium Benzoate

Liminal BioSciences Ltd.

Phase 3
No programs
Approved
No programs

Analysis

Trial Status

1

clinical trials

Recruiting1 · 100%

Clinical Trials

Trial Activity

Study of Sodium Phenylbutyrate (ACER-001) for the Treatment of Pediatric and Adults Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)
Recruiting·—·Phase 2·NCT06773026·24 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)